[AbCellera](https://www.abcellera.com/) is a biotech company, they are doing great in creating antibodies against multiple diseases and viruses, check the website for more information, I'll be showing financials. They have innovated in the sector since IPO, but the only thing holding them back was their balance sheet. They had one of the worst PE ratios, as well as not being profitable, and many other financial shortcomings. On Monday after hours, they reported 2020 full year results, and it was great. 1,908% revenue increase year over year ($230 mill), EPS of .53 basic, .45 diluted, compared to .01 loss per share in 2019, $119 million in net earnings compared to a $1 million loss in 2019. Here's a [Yahoo Finance article](https://finance.yahoo.com/news/abcellera-reports-full-2020-business-200500028.html) on the full results. I don't see much holding this stock back from reentering it's IPO price of around $60 in the coming 2-3 months. It popped up 27% today, $33.96 as of writing. I'm not going to do a full DD, but hopefully this brought some apes attention to this stock, sorry for not talking about it a few days ago when it was cheaper. Not financial advice, yada yada.